Menu
Curie Logo
Donate
  • Home

Clinical trials - page 4

Essais cliniques
Search for a clinical trial
Filter

195 result(s)

  • Paris
    CP-START 001
    Open-label, First-in-Human, Phase 1/2 Study with Dose Escalation and Expansion of STAR0602, a Bifunctional Antibody Fusion Targeting Selective T Cell Receptors (TCR), in Patients with Unresectable, Locally Advanced, or Metastatic Antigen-Rich Solid Tumors (START-001).

    CHRISTOPHE LE TOURNEAU

  • Childhood and adolescent cancers
    Paris
    CRISP (IC 2017-08 / ITCC 053)
    A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies.

    ISABELLE AERTS GAJDOS

  • Breast cancer
    Saint-Cloud
    CT7001_003 (SUMIT ELA)
    A Phase 1b/2 Open-label Study of Samuraciclib in Combination with Elacestrant in;Participants with Metastatic or Locally Advanced Hormone Receptor-positive and Human;Epidermal Growth Factor Receptor 2-negative Breast Cancer.

    FRANCOIS-CLEMENT BIDARD

  • Lung cancer
    Paris
    CodeBreak202
    A Phase 3, Multicenter, Randomized, Open-label;Study Evaluating Efficacy of Sotorasib Platinum;Doublet Combination Versus Pembrolizumab;Platinum Doublet Combination as a Front-Line;Therapy in Subjects With Stage IV or Advanced;Stage IIIB/C Nonsquamous NonÀSmall Cell Lung;Cancers, Negative for PD-L1, and Positive for;KRAS p.G12C (CodeBreaK 202)

    NICOLAS GIRARD

  • Saint-Cloud
    D7407C00001- SOUNDTRACK-E
    A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies (Soundtrack-E).

    CLEMENTINE SARKOZY

  • Saint-Cloud
    DOLAF
    An International Multicenter Phase II Trial of Durvalumab (MEDI4736) Plus OLAparib Plus Fulvestrant in Metastatic or Locally Advanced ER-positive, HER2-negative Breast Cancer Patients Selected Using Criteria That Predict Sensitivity to Olaparib

  • Cancers gynécologiques
    Saint-Cloud
    DS6000-109
    A Phase 2/3, Multicenter, Randomized Study of Raludotatug;Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate,;in Subjects with Platinum-resistant, High-grade Ovarian, Primary;Peritoneal, or Fallopian Tube Cancer.

    DIANA BELLO ROUFAI

  • Saint-Cloud
    DS8201-A-U207 DESTINY CRC02
    A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Participants With HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02)

  • Cancers gynécologiques
    Saint-Cloud
    E7386-J081-102_(PENT-02)
    An Open-Label Study of E7386 in Combination With Other;Anticancer Drug(s) in Subjects With Solid Tumors.

    DIANA BELLO ROUFAI

  • Paris
    EGL-001 (EGL-121)
    First-in-human Trial of EGL-001 in Patients with Selected Advanced And/·or Metastatic Solid Tumors

    EDITH BORCOMAN

  • Saint-Cloud
    EMBER-2 (J2J-MC-JZLB)
    EMBER-2: A Phase 1, Open-Label, Preoperative Window Study Evaluating the Biological Effects of LY3484356 in Post-menopausal Women With Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer.

    FRANCOIS-CLEMENT BIDARD

  • Saint-Cloud
    EPIC 1511
    Impact of Early Palliative Care on Overall Survival of Patients With Metastatic Upper Gastrointestinal Cancers, Treated With First-line Chemotherapy: a Randomized Phase III Trial.

    ELISABETH LUCCHI

  • Saint-Cloud
    EPITOP 01
    Elderly Cancer PatIents Treated for Advanced or Metastatic Melanoma or NSCLC, Safety and qualiTy of Life Under immunOtheraPies: a Phase IV Trial

    MICHAEL BRINGUIER

  • Saint-Cloud
    ER-One (IC 2020-04)
    A Double-blind Randomized Non-inferiority Trial of Erector Spinae Block (ESP) Versus Paravertebral Block (PVB) Before Breast Cancer Surgery: Effects on Acute Postoperative Pain.

    ALINE ALBI-FELDZER

  • Lung cancer
    Paris
    EVOKE-SCLC-04 - (GS-US-600-6165)
    Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (EVOKE-SCLC-04).

    NICOLAS GIRARD

  • Saint-Cloud
    Epi R-CHOP
    A Phase Ib-II Study of Tazemetostat (EPZ-6438) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or High Risk Follicular Lymphoma (FL) Patients Treated by R-CHOP

    CLEMENTINE SARKOZY

  • Breast cancer
    Paris
    EvoPAR-Breast01
    A Randomised, Open-Label, Phase III Study of AZD5305 Plus Camizestrant versus Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy for the First-Line Treatment of BRCA1, BRCA2, or PALB2-mutated Patients with Hormone Receptor-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified) Advanced Breast Cancer ().

    DELPHINE LOIRAT

  • Saint-Cloud
    FAST
    French Aspirin Study in Essential Thrombocythemia: an Open and Randomized Study

    SANDRA MALAK

  • Saint-Cloud
    FIGARO
    Feasibility and Accuracy of Lymph-node (LN) Restaging by Sentinel LN Procedure and Axillary LN Dissection in Ipsilateral Invasive Breast Cancer Relapse

  • Saint-Cloud
    FORWARD-1
    FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer

    ANNE DONNADIEU

  • Breast cancer
    Paris, Saint-Cloud
    Flamingo-01
    A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01).

    FRANCOIS-CLEMENT BIDARD

  • Saint-Cloud
    GANEA 3
    Sentinel Lymph Node After Neoadjuvant Chemotherapy in Breast Carcinoma.

    EUGENIE GUILLOT

  • Saint-Cloud
    GATA
    A Phase II Trial Evaluating Combination of Atezolizumab, With Venetoclax and Obinutuzumab for Relapsed/Refractory Lymphomas

    CAROLE SOUSSAIN

  • Kidney cancer
    Paris
    GETUG-StORM-01
    A Randomized Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases.

  • Cancers gynécologiques
    Paris
    GLORIOSA
    Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA).

    MANUEL RODRIGUES

  • Lymphoma
    Saint-Cloud
    GO43878(GLOBRYTE)
    A PHASE III, OPEN-LABEL, MULTICENTER,;RANDOMIZED STUDY EVALUATING GLOFITAMAB AS;A SINGLE AGENT VERSUS INVESTIGATORÀS CHOICE;IN PATIENTS WITH RELAPSED/REFRACTORY;MANTLE CELL LYMPHOMA.

    CLEMENTINE SARKOZY

  • Cervical cancer
    Saint-Cloud
    GYNET
    A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination With Carboplatin Plus Paclitaxel and/or Pembrolizumab in Patients With Locally Advanced/Metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/Relapsing After at Least One Prior Systemic Chemotherapy.

    DIANA BELLO ROUFAI

  • Lung cancer
    Paris
    HARMONi-3
    A randomized, controlled, multiregional Phase 3 study of ivonescimab combined with chemotherapy versus pembrolizumab combined with chemotherapy for the first-line treatment of metastatic squamous non-small cell lung cancer.

    PAULINE DU RUSQUEC

  • Breast cancer
    Paris, Saint-Cloud
    HEROES
    De-escalation of medical treatments in HER2-positive metastatic breast cancer in case of long-term persistent response and undetectable minimal residual disease assessed by circulating tumor DNA.

    DIANA BELLO ROUFAI

  • Childhood and adolescent cancers
    Paris
    HR-NBL2
    High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

    GUDRUN SCHLEIERMACHER

<
1 ...4...7
>